Developer docs
API playgroundTry for free, no card

Search company profiles

Juniper Genomics

Full company profile

uuid0000f2n

Namestring
Juniper Genomics
Legal namestring
Embryome Inc
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Juniper Genomics is a Toronto-based health technology company that provides advanced preimplantation genetic testing (PGT) for IVF patients in North America through partnerships with select fertility clinics. The company operates a two-step screening platform: PGT-A, a standard chromosome-counting test used as the entry point, and PGT-G, a deeper whole-genome and transcriptome analysis that combines embryo biopsy data with parental blood samples (trio sequencing) to uncover variants linked to embryo viability, pregnancy success, and over 6,000 genetic conditions. Juniper reports sequencing 99% of each embryo's 3 billion base pairs at clinical-grade accuracy and analyzing more than 9 billion data points per embryo—compared with 46 data points in standard PGT-A—achieving claimed detection of over 85% of adverse pregnancy outcomes versus roughly 50% with standard testing and reported live birth rates up to 85% per transfer versus ~55%.

The technology stack combines whole-genome sequencing, RNA transcriptome analysis, parental trio data, and single-cell resolution analysis to minimize false-positive mosaicism. Reports are delivered to clinics within 3-4 weeks and include genetic counseling. Juniper generates revenue through professional-services testing fees (PGT-A as entry, PGT-G as premium expansion), executed via a B2B2C go-to-market in which the company provides biopsy kits, phlebotomy kits, and shipping materials to partner clinics and those clinics offer testing to their IVF patients. Pricing is not publicly disclosed and contracts are multi-year; genetic counseling is bundled into the testing service.

Juniper is privately held and incorporated in Ontario as Embryome Inc. It raised $4.6 million in seed funding in June 2025 led by Company Ventures, with participation from Amboy Street Ventures, Blue Collective, Dria Ventures, Flybridge, Innospark Ventures, MBX Capital, and research support from Genome Canada and Genome Quebec. Leadership comprises CEO and Acting CSO Jeremy Grushcow, Chief Product Officer Kaylene Ready, and Medical Director Lee Shulman, supported by an advisory board drawn from Harvard Medical School, University of Toronto, Duke, and Baylor College of Medicine. The company is in early-adopter commercial phase, operating across Canada and the U.S., and was named to Fast Company's "Next Big Things in Tech 2025."

Short descriptiontext

Juniper Genomics provides advanced preimplantation genetic testing for IVF patients through partner fertility clinics in North America. Its two-step platform combines PGT-A chromosome testing with PGT-G whole-genome and transcriptome sequencing using trio analysis to improve embryo selection and IVF success rates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preimplantation genetic testing, embryo screening, IVF genomics, whole genome sequencing, reproductive genetics
Industry2 codes
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Reproductive Genetic Testing Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1PGT-A Testing
TypeProfessional Services
Description

Chromosome testing service for IVF embryos, providing early look at embryo health by checking chromosome count. This is the entry point in the two-step pathway.

junipergenomics.com
2PGT-G Testing
TypeProfessional Services
Description

Comprehensive whole-genome and transcriptome testing service that provides deep insight into embryo genetics. Revenue generated from the expanded analysis for embryos beyond PGT-A.

junipergenomics.com
3Genetic Counseling
TypeProfessional Services
Description

Genetic counseling services provided before and after testing, included at no additional cost as part of the testing service offering.

junipergenomics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1PGT-A (Chromosome Testing)
ModelOtherBilling cadenceMulti-year contract
Notes

Entry-level testing starting point; pricing not publicly disclosed

junipergenomics.com
2PGT-G (Whole Genome Testing)
ModelOtherBilling cadenceMulti-year contract
Notes

Expanded whole-genome and transcriptome testing; pricing not publicly disclosed

junipergenomics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Juniper Genomics provides preimplantation genetic testing (PGT) services for IVF embryos through a two-step platform. Step 1 is PGT-A, a chromosome-counting test examining 46 data points; Step 2 is PGT-G, a whole-genome and transcriptome sequencing test analyzing over 9 billion data points per embryo using trio analysis with parental blood samples. The service is delivered through partner IVF clinics, with genetic counseling included and reports delivered within 3-4 weeks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 85% live birth rate per embryo transfer compared to 55% with standard chromosome testing
+3 more records
Product overview1 text field

Juniper Genomics offers a unified two-step embryo screening platform called Juniper PGT, comprising PGT-A (Preimplantation Genetic Testing for Aneuploidy) as the initial core product and PGT-G as an advanced add-on module. PGT-A provides standard chromosome counting (46 data points), while PGT-G delivers comprehensive whole-genome and transcriptome sequencing (over 9 billion data points) with trio analysis using parental blood samples. Both tests run from a single biopsy, with PGT-G expanding to whole-genome clarity when patients are ready. The platform identifies genetic causes for over 85% of adverse pregnancy outcomes compared to approximately 50% with standard PGT-A testing.

Product and service3 records
1PGT-A (Preimplantation Genetic Testing for Aneuploidy)
CategoryReproductive Genetic Testing Services
Description

First-step chromosome testing service for IVF embryos that checks each embryo has the correct number of chromosomes (46 data points across 23 chromosome pairs), a key factor in successful implantation and pregnancy. Run from a single embryo biopsy and included as the entry point in Juniper's two-step pathway.

2PGT-G (Preimplantation Genetic Testing - Genome)
CategoryReproductive Genetic Testing Services
Description

Advanced whole-genome and transcriptome sequencing test for IVF embryos that examines nearly all of an embryo's genetic code (over 9 billion data points), uncovering variants linked to embryo viability, pregnancy success, and approximately 6,000 known genetic conditions. Uses trio analysis with parental blood samples plus embryo transcriptome sequencing. Identifies causes for over 85% of adverse pregnancy outcomes versus ~50% with standard PGT-A testing.

3Genetic Counseling
CategoryReproductive Genetic Testing Services
Description

Genetic counseling services provided before and after testing, included at no additional cost as part of Juniper's testing service offering to support patients and clinicians in interpreting results.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Nova IVF
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Inaugural launch clinic partner where Dr. Meera Shah, MD, REI serves on Juniper's Advisory Board. Dr. Shah describes Juniper as 'the only startup building in PGT that understands what our patients need.'

junipergenomics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Myriad Genetics is a large established genetic testing company with offerings in women's health and reproductive genetics including carrier screening. It operates broadly in the reproductive health space but is not specialized in IVF embryo testing like Juniper.

TypeBroad incumbent
Description

Invitae (now part of Labcorp) provides comprehensive genetic testing including reproductive and carrier screening services. It operates across multiple genetic testing categories and competes more broadly than Juniper's focused IVF embryo testing.

TypeDirect peer
Description

Natera offers the Empower PGT-A test and broader reproductive genetics portfolio including Vistara single-gene PGT. As a publicly traded genetic testing company, it is a direct competitor in the embryo testing space with significant scale and reimbursement infrastructure.

4Baylor Genetics
TypeEmerging player
Description

Baylor Genetics offers comprehensive genetic testing including reproductive diagnostics with expertise in rare disease and prenatal screening. It has partial overlap with Juniper's embryo genetic testing focus and strong clinical reputation in the genomics community.

TypeEmerging player
Description

Orchid offers whole-genome embryo screening for IVF couples, with a focus on polygenic disease risk. It is an emerging competitor in the comprehensive embryo testing category where Juniper also operates, targeting similar tech-forward IVF patients.

TypeBroad incumbent
Description

Labcorp is a major clinical laboratory network with reproductive and prenatal genetic testing capabilities, including PGT services through acquired businesses. It competes in the broader reproductive diagnostics market with scale advantages but less specialization than Juniper.

7Genomic Prediction
TypeDirect peer
Description

Genomic Prediction offers PGT-P, a polygenic embryo screening test for IVF patients. While focused on polygenic risk scores rather than whole-genome sequencing, it competes in the advanced embryo testing segment targeting the same IVF patient population.

8Reprogenetics
TypeDirect peer
Description

Reprogenetics is a specialized PGT laboratory offering PGT-A, PGT-M, and PGT-SR with extensive IVF clinic partnerships. It directly competes in the same preimplantation genetic testing category with similar service offerings to IVF clinics.

TypeDirect peer
Description

CooperGenomics is an established reproductive genetics laboratory offering PGT-A, PGT-M, and PGT-SR services to IVF clinics. It competes directly with Juniper in the IVF preimplantation genetic testing market with a broader established footprint.

TypeDirect peer
Description

Igenomix is one of the world's largest providers of PGT and reproductive genetics services, directly competing with Juniper's embryo testing offerings across IVF clinics globally. Both companies offer PGT-A and expanded PGT services to IVF patients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Juniper Genomics

Reproductive Genetic Testing Servicesjunipergenomics.com

Juniper Genomics provides advanced preimplantation genetic testing for IVF patients through partner fertility clinics in North America. Its two-step platform combines PGT-A chromosome testing with PGT-G whole-genome and transcriptome sequencing using trio analysis to improve embryo selection and IVF success rates.

What Juniper Genomics does

Juniper Genomics is a Toronto-based health technology company that provides advanced preimplantation genetic testing (PGT) for IVF patients in North America through partnerships with select fertility clinics. The company operates a two-step screening platform: PGT-A, a standard chromosome-counting test used as the entry point, and PGT-G, a deeper whole-genome and transcriptome analysis that combines embryo biopsy data with parental blood samples (trio sequencing) to uncover variants linked to embryo viability, pregnancy success, and over 6,000 genetic conditions. Juniper reports sequencing 99% of each embryo's 3 billion base pairs at clinical-grade accuracy and analyzing more than 9 billion data points per embryo—compared with 46 data points in standard PGT-A—achieving claimed detection of over 85% of adverse pregnancy outcomes versus roughly 50% with standard testing and reported live birth rates up to 85% per transfer versus ~55%.

The technology stack combines whole-genome sequencing, RNA transcriptome analysis, parental trio data, and single-cell resolution analysis to minimize false-positive mosaicism. Reports are delivered to clinics within 3-4 weeks and include genetic counseling. Juniper generates revenue through professional-services testing fees (PGT-A as entry, PGT-G as premium expansion), executed via a B2B2C go-to-market in which the company provides biopsy kits, phlebotomy kits, and shipping materials to partner clinics and those clinics offer testing to their IVF patients. Pricing is not publicly disclosed and contracts are multi-year; genetic counseling is bundled into the testing service.

Juniper is privately held and incorporated in Ontario as Embryome Inc. It raised $4.6 million in seed funding in June 2025 led by Company Ventures, with participation from Amboy Street Ventures, Blue Collective, Dria Ventures, Flybridge, Innospark Ventures, MBX Capital, and research support from Genome Canada and Genome Quebec. Leadership comprises CEO and Acting CSO Jeremy Grushcow, Chief Product Officer Kaylene Ready, and Medical Director Lee Shulman, supported by an advisory board drawn from Harvard Medical School, University of Toronto, Duke, and Baylor College of Medicine. The company is in early-adopter commercial phase, operating across Canada and the U.S., and was named to Fast Company's "Next Big Things in Tech 2025."

Juniper Genomics firmographics

Firmographics
Name
Juniper Genomics
Legal name
Embryome Inc
Website
https://junipergenomics.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Juniper Genomics provides advanced preimplantation genetic testing for IVF patients through partner fertility clinics in North America. Its two-step platform combines PGT-A chromosome testing with PGT-G whole-genome and transcriptome sequencing using trio analysis to improve embryo selection and IVF success rates.
Ownership category
akta.pro rank

Juniper Genomics industry classification

Industry
Product category
Reproductive Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Preimplantation genetic testing
  • Embryo screening
  • IVF genomics
  • Whole genome sequencing
  • Reproductive genetics

Where Juniper Genomics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Juniper Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. PGT-A Testing: Chromosome testing service for IVF embryos, providing early look at embryo health by checking chromosome count. This is the entry point in the two-step pathway.
  2. PGT-G Testing: Comprehensive whole-genome and transcriptome testing service that provides deep insight into embryo genetics. Revenue generated from the expanded analysis for embryos beyond PGT-A.
  3. Genetic Counseling: Genetic counseling services provided before and after testing, included at no additional cost as part of the testing service offering.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPGT-A (Chromosome Testing)
OtherMulti-year contractPGT-G (Whole Genome Testing)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Juniper Genomics product offering

Product offering

Core offering

Juniper Genomics provides preimplantation genetic testing (PGT) services for IVF embryos through a two-step platform. Step 1 is PGT-A, a chromosome-counting test examining 46 data points; Step 2 is PGT-G, a whole-genome and transcriptome sequencing test analyzing over 9 billion data points per embryo using trio analysis with parental blood samples. The service is delivered through partner IVF clinics, with genetic counseling included and reports delivered within 3-4 weeks.

Product overview

Juniper Genomics offers a unified two-step embryo screening platform called Juniper PGT, comprising PGT-A (Preimplantation Genetic Testing for Aneuploidy) as the initial core product and PGT-G as an advanced add-on module. PGT-A provides standard chromosome counting (46 data points), while PGT-G delivers comprehensive whole-genome and transcriptome sequencing (over 9 billion data points) with trio analysis using parental blood samples. Both tests run from a single biopsy, with PGT-G expanding to whole-genome clarity when patients are ready. The platform identifies genetic causes for over 85% of adverse pregnancy outcomes compared to approximately 50% with standard PGT-A testing.

Differentiator

Problem solved

Functional benefit

Products and services

  • PGT-A (Preimplantation Genetic Testing for Aneuploidy) First-step chromosome testing service for IVF embryos that checks each embryo has the correct number of chromosomes (46 data points across 23 chromosome pairs), a key factor in successful implantation and pregnancy. Run from a single embryo biopsy and included as the entry point in Juniper's two-step pathway.
  • PGT-G (Preimplantation Genetic Testing - Genome) Advanced whole-genome and transcriptome sequencing test for IVF embryos that examines nearly all of an embryo's genetic code (over 9 billion data points), uncovering variants linked to embryo viability, pregnancy success, and approximately 6,000 known genetic conditions. Uses trio analysis with parental blood samples plus embryo transcriptome sequencing. Identifies causes for over 85% of adverse pregnancy outcomes versus ~50% with standard PGT-A testing.
  • Genetic Counseling Genetic counseling services provided before and after testing, included at no additional cost as part of Juniper's testing service offering to support patients and clinicians in interpreting results.

Quantifiable outcome

  • Up to 85% live birth rate per embryo transfer compared to 55% with standard chromosome testing
  • +3 more outcomes

Companies that use Juniper Genomics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Juniper Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Juniper Genomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Nova IVFcoreStrategic or Co-development PartnerInaugural launch clinic partner where Dr. Meera Shah, MD, REI serves on Juniper's Advisory Board. Dr. Shah describes Juniper as 'the only startup building in PGT that understands what our patients need.'

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Juniper Genomics competitors and assessment

Company assessment

Broad incumbents

  • Myriad Genetics: Myriad Genetics is a large established genetic testing company with offerings in women's health and reproductive genetics including carrier screening. It operates broadly in the reproductive health space but is not specialized in IVF embryo testing like Juniper.
  • Invitae: Invitae (now part of Labcorp) provides comprehensive genetic testing including reproductive and carrier screening services. It operates across multiple genetic testing categories and competes more broadly than Juniper's focused IVF embryo testing.
  • Labcorp / Esoterix Genetic Laboratories: Labcorp is a major clinical laboratory network with reproductive and prenatal genetic testing capabilities, including PGT services through acquired businesses. It competes in the broader reproductive diagnostics market with scale advantages but less specialization than Juniper.

Direct peers

  • Natera: Natera offers the Empower PGT-A test and broader reproductive genetics portfolio including Vistara single-gene PGT. As a publicly traded genetic testing company, it is a direct competitor in the embryo testing space with significant scale and reimbursement infrastructure.
  • Genomic Prediction: Genomic Prediction offers PGT-P, a polygenic embryo screening test for IVF patients. While focused on polygenic risk scores rather than whole-genome sequencing, it competes in the advanced embryo testing segment targeting the same IVF patient population.
  • Reprogenetics: Reprogenetics is a specialized PGT laboratory offering PGT-A, PGT-M, and PGT-SR with extensive IVF clinic partnerships. It directly competes in the same preimplantation genetic testing category with similar service offerings to IVF clinics.
  • CooperGenomics (CooperSurgical): CooperGenomics is an established reproductive genetics laboratory offering PGT-A, PGT-M, and PGT-SR services to IVF clinics. It competes directly with Juniper in the IVF preimplantation genetic testing market with a broader established footprint.
  • Igenomix (Vitrolife): Igenomix is one of the world's largest providers of PGT and reproductive genetics services, directly competing with Juniper's embryo testing offerings across IVF clinics globally. Both companies offer PGT-A and expanded PGT services to IVF patients.

Emerging players

  • Baylor Genetics: Baylor Genetics offers comprehensive genetic testing including reproductive diagnostics with expertise in rare disease and prenatal screening. It has partial overlap with Juniper's embryo genetic testing focus and strong clinical reputation in the genomics community.
  • Orchid Health: Orchid offers whole-genome embryo screening for IVF couples, with a focus on polygenic disease risk. It is an emerging competitor in the comprehensive embryo testing category where Juniper also operates, targeting similar tech-forward IVF patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Juniper Genomics social profiles

Digital presence

Juniper Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Juniper Genomics leadership team

Management profile

Number of profiles

Profiles8 records

Juniper Genomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Juniper Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juniper Genomics

What does Juniper Genomics do?

Juniper Genomics provides preimplantation genetic testing (PGT) services for IVF embryos through a two-step platform. Step 1 is PGT-A, a chromosome-counting test examining 46 data points; Step 2 is PGT-G, a whole-genome and transcriptome sequencing test analyzing over 9 billion data points per embryo using trio analysis with parental blood samples. The service is delivered through partner IVF clinics, with genetic counseling included and reports delivered within 3-4 weeks.

Is Juniper Genomics a public or private company?

Juniper Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Juniper Genomics founded?

Juniper Genomics was founded in 2025. It employs 11 to 50 people.

Where is Juniper Genomics based?

Juniper Genomics is headquartered in Toronto, Canada, in the North America region.

How does Juniper Genomics make money?

Three revenue lines are on record. PGT-A Testing is the primary driver. The others are PGT-G Testing and genetic Counseling.

Who are Juniper Genomics's main competitors?

Broad incumbents on record are Myriad Genetics, Invitae and Labcorp / Esoterix Genetic Laboratories. Direct peers are Natera, Genomic Prediction, Reprogenetics, CooperGenomics (CooperSurgical) and Igenomix (Vitrolife). Emerging players are Baylor Genetics and Orchid Health.

Does Juniper Genomics have an API?

No public API is recorded for Juniper Genomics.

What industry is Juniper Genomics in?

Juniper Genomics's product category is Reproductive Genetic Testing Services. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebJuniper Genomics Named to Fast Company's "Next Big Things in Tech 2025" ListJuniper Genomics, a Toronto-based health-tech company, has been named to Fast Company's "Next Big Things in Tech 2025" list for its whole-genome and transcriptome embryo screening platform that provides comprehensive embryo health assessment for IVF patients. The company launched in June 2025 with $4.6 million in seed funding led by Company Ventures, with participation from Innospark Ventures, MBX Capital, Amboy Street Ventures, Dria Ventures, and Blue Collective. Juniper also announced the formation of a Clinical Advisory Board featuring leading reproductive and women's health experts.Med-Tech InsightsJuniper Genomics debuts ‘world first’ whole-genome and transcriptome testJuniper Genomics launched its whole-genome and transcriptome IVF testing platform, backed by a $4.6M seed round led by Company Ventures. The test replaces most preimplantation genetic testing and screens for specific genetic changes linked to adverse outcomes. The company plans to expand commercial reach and grow its teams.HLTHJuniper Genomics Launches with $4.6M for Advanced Embryo ScreeningJuniper Genomics has launched with $4.6 million in seed funding to commercialize its whole genome and transcriptome sequencing test for embryo screening. The Canada-based company plans to use the capital for commercial expansion and research partnerships as it deploys its platform to early adopter clinics across North America. This new approach aims to improve IVF success rates by analyzing millions of genetic markers while avoiding controversial polygenic risk scores.Clinical Lab ProductsJuniper Genomics Debuts Whole-Genome and Transcriptome TestJuniper Genomics has launched publicly with $4.6 million in seed funding to offer a comprehensive whole-genome and transcriptome embryo screening platform designed to improve IVF outcomes. The company's test replaces most existing preimplantation genetic tests by analyzing millions of genetic markers, including those tied to IVF failure and postnatal conditions, and is currently rolling out in early adopter IVF clinics across North America. Juniper plans to use the funding to scale operations, enhance its bioinformatics platform, and expand research collaborations.GlobeNewswireA New Era for Embryo Screening: Juniper Genomics Debuts with World’s First Whole-Genome and Transcriptome TestJuniper Genomics launched its public embryo screening test, a whole-genome and transcriptome assay, after raising $4.6 million in seed funding led by Company Ventures. The test analyzes millions of genetic markers to assess embryo viability, replacing most existing preimplantation genetic testing. The company plans to expand commercial reach and grow its teams.GlobeNewswireA New Era for Embryo Screening: Juniper Genomics Debuts with World’s First Whole-Genome and Transcriptome TestJuniper Genomics launched its public embryo screening test, a whole-genome and transcriptome assay, after a $4.6 million seed round led by Company Ventures. The test analyzes millions of genetic markers to assess embryo viability, replacing most existing preimplantation genetic testing. The company plans to expand commercial reach and grow its teams.